The CSL share price is a sleeping dividend giant. Here's why

CSL shares aren't considered serious dividend payers. But this could be a costly mistake.

| More on:
A tired healthcare or lab worker sleeps on her desk

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The ASX is home to many dividend heavyweights
  • But CSL shares aren't usually considered among these
  • Here's why that assumption may be a mistake

 The CSL Limited (ASX: CSL) share price has been a staple of the S&P/ASX 200 Index (ASX: XJO) for decades now. In fact, CSL has spent its time over the past decade or so climbing up from the middle of the ASX 200 pack to the number three position on the Index that it now occupies.

But unlike its fellow top ASX 200 shares, such as BHP Group Ltd (ASX: BHP) or the big four banks, CSL has never been regarded as a dividend heavyweight. 

A quick look at the CSL share price today will probably tell you why. Right now, CSL has a trailing dividend yield of just 1.11%. That only comes partially franked too.

In stark contrast, BHP shares currently offer a fully-franked trailing yield of 8.86% right now. Commonwealth Bank of Australia (ASX: CBA) is at a fully-franked 4.2%, while Westpac Banking Corp (ASX: WBC) offers 5.62%.

So dividend-chasing income investors probably won't take too long in deciding which shares to have in their portfolios. But those investors might want to take a second look because all is not quite as it seems at first glance. 

Yes, you won't get as much dividend income upfront buying CSL shares as you would BHP or one of the big four banks. But CSL could well be a sleeping divided giant and one whose dividends might approach, or even exceed, the level of income offered by ASX's other heavyweights in just a few years.

Here's why.

Why the CSL share price could be a sleeping dividend giant

CSL first started paying its investors dividends back in 2013. The company's very first dividend payment was a final dividend worth 52 US cents per share. In 2014, the company doled out annual dividend payments worth US$1.13 per share.

But just five years later in 2019, CSL was up to paying out US$1.85 in dividends per share. By 2022, this had risen again to a total of US$2.22 per share.

In US dollar terms, CSL has consistently raised its annual dividend every single year since 2013. Because of currency exchange rates, we can't say the same for its dividends in Aussie dollar terms. But the trend is clear.

In 2023 so far, this trend has continued too. The interim dividend that investors received only earlier this month came in at US$1.07 per share. That was a significant hike over 2022's corresponding payment of US$1.04 per share.

Between 2014 and 2022, CSL's annual dividend rocketed by a cumulative 96.5%. If CSL's dividends keep rising at this level over the next eight years, investors will be bagging US$4.36 in dividends per share by the year 2030. That's $6.54 per share in Australian dollars at the current exchange rate.

If that were to occur (which is by no means guaranteed), it would be highly lucrative for long-term investors, and would finally make CSL an ASX dividend heavyweight.

So this just proves that you can't judge an ASX divided share by the yield on its cover. By the time the 'sleeping giant' awakens, it might be too late to nab the shares at a good share price.

 

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended Westpac Banking. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Mesoblast just cleared a key FDA hurdle. So why are investors exiting?

Mesoblast shares slide to a 2-month low despite positive FDA feedback on its lead cell therapy product.

Read more »

Man leaps as he runs along the street.
Healthcare Shares

ASX 300 stock jumps 6% on strong half-year results and cash flow surge

Let's see how this medical device company performed during the first half.

Read more »

Two boys lie in the grass arm wrestling.
Healthcare Shares

Is CSL or Sonic Healthcare the smarter ASX healthcare share buy?

This ASX heavyweight has potential to deliver superior returns but is more volatile.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Up more than 800% in a year. Why this ASX medical tech stock just hit an all-time high

4DMedical shares have surged over 800% as US hospital adoption and FDA clearance drive momentum.

Read more »

A retiree relaxing in the pool and giving a thumbs up.
Healthcare Shares

1 ASX dividend stock down 36% I'd buy right now

This business looks like it’s priced too cheaply.

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

Why investors are watching this ASX healthcare stock

A fresh clinical update has been released.

Read more »

A Sonic Healthcare medical researcher wearing a white coat sits at her desk in a laboratory conducting a COVID-19 test
Healthcare Shares

This biotech is up more than 20% on new deal news

Revenue will flow under this global deal just announced.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

The next 3 years could be huge for this ASX healthcare stock. Here's why

Today's update has put this ASX healthcare stock back in the spotlight as investors reassess its long-term growth potential.

Read more »